Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

42 results about "Neurological impairment" patented technology

Neurological impairment refers to a broad group of disorders in which the central nervous system does not function properly and leads to some form of physical or mental problems.

Multi-user smartglove for virtual environment-based rehabilitation

A low-cost, virtual environment, rehabilitation system and a glove input device for patients suffering from stroke or other neurological impairments for independent, in-home use, to improve upper extremity motor function, including hand and finger control. The system includes a low-cost input device for tracking arm, hand, and finger movement; an open source gaming engine; and a processing device. The system is controllable to provide four types of multiple patient / user interactions: competition, cooperation, counter-operative, and mixed.
Owner:NORTHEASTERN UNIV

System for traumatic brain injury detection using oculomotor tests

Embodiments of the present invention comprises apparatuses and methods of measuring levels of neurological impairment. Certain embodiments of the invention comprise a headset that emits light into the user's eyes and the system tracks the pupils' orientation, movement, contraction and dilation. In specific embodiments, the headset can run a battery of tests and calculate a score indicating the user's level of neurological impairment.
Owner:UNIV OF IOWA RES FOUND +1

Lipid Emulsions in the Treatment of Systemic Poisoning

The present invention provides lipid emulsions and methods of intravenously administering lipid emulsions to treat systemic toxicity caused by foreign lipophilic and amphiphilic substances. In particular, methods are provided to treat cardiovascular impairment, such as cardiotoxicity, asystole and ischemia of the brain and heart, and neurological impairments, such as seizures and comas, caused by foreign lipophilic and amphiphilic substances, including cardiovascular impairment caused by local anesthetics, tricyclic antidepressants, sodium channel blockers, and calcium channel blockers.
Owner:RESQ PHARMA INC

Pacifier system for stimulating and entraining the human orofacial system

This application discusses systems and method for entraining oromotor pattern development, such as the suck, in the orofacial system of an infant having neurological impairments or developmental disabilities. The system includes a baglet, an entrainment device, and a processor. In varying examples, the system additionally includes one or a combination of: a baglet pressure sensor, a memory, a timing circuit, a valve, a receiver assembly, a display device, and one or more data acquisition, data analysis, and stimulus-control software. Options and variations for each feature of the system are various. The present systems provide patterned, rhythmic stimulation to the infant's orofacial system to stimulate and entrain brain development, such as oromotor pattern development.
Owner:UNIVERSITY OF KANSAS +1

High potency dopaminergic treatment of neurological impairment associated with brain injury

InactiveUS7943632B2BiocidePeptide/protein ingredientsConsciousness DisordersInjury brain
Methods and compositions are described for treating impaired neurological function, including altered state of consciousness disorders, in an individual who has sustained a brain injury comprising administering to the individual apomorphine. Methods and compositions are described for treating impaired neurological function, including altered state of consciousness disorders, in an individual who has sustained a brain injury comprising administering to the individual at least 1000 mg or more of L-dopa (levodopa) per day. The use of potent dopaminergic agents to stimulate emergence from an altered consciousness state, such as a coma, is disclosed.
Owner:NEUROHEALING PHARMA INC

Wearable treatment device and device control method

The present invention discloses a wearable treatment device and a device control method. The wearable treatment device comprises a light output unit connected with a processor and outputting the light of an appointed wavelength; an electrical output unit connected with the processor and outputting a current value within an appointed range; an output electrode connected with the electrical output unit and used for outputting an electroencephalogram signal to a corresponding part; an electroencephalogram detection unit used for detecting a brain wave signal and transmitting the brain wave signal to the processor; a body surface detection electrode connected with the electroencephalogram detection unit and used for detecting an electroencephalogram signal of a human body appointed part. According to the embodiment of the present invention, the wearable treatment device can interpose the human body function by the photo stimulation and the electrical stimulation, and enables the excitability of an ascending activating system to be reduced by adjusting the electrical activity of neuronal cells, thereby readjusting the brain cells, helping the brain to recover from the over fatigue, and improving the sleep quality. According to the present invention, by applying the photo stimulation and the electrical stimulation simultaneously or in different alternative and sequential combination manners, the nervous system disorders can be improved more effectively.
Owner:HANGZHOU ETK INTELLIGENT TECH CO LTD

Exosome-loaded GelMA hydrogel microneedle as well as preparation method and application thereof

PendingCN113940949ARelieve complicationsImprove neurological deficits and other symptomsNervous disorderMicroneedlesNeurological impairmentExosome
The invention provides an exosome-loaded GelMA hydrogel microneedle as well as a preparation method and application thereof, and belongs to the technical field of biological medicines and molecular biology. The invention researches and verifies that the exosome microneedle (GelMA-MNs-MSC-Exo) derived from MSC loaded by GelMA hydrogel has the effects of relieving SCI complications, improving prognosis and the like for the first time. Specifically, the GelMA-MNs-MSC-Exo can effectively improve the symptoms such as neurological impairment after SCI, so that the GelMA-MNs-MSC-Exo is a potential treatment method, can relieve the local microenvironment after SCI and promote the recovery of neurological functions, and has good practical application value.
Owner:SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI

Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

The present invention relates to novel 3-phenyl-azetidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-azetidine derivatives of the invention and to the use of these compounds for therapeutic applications.
Owner:NSAB FILIAL AF NEUROSEARCH SVERIGE

Methods and apparatus for teaching reading and math skills to individuals with dyslexia, dyscalculia, and other neurological impairments

ActiveUS20110287395A1Board gamesReadingDeep dyslexiaNeurological impairment
The present invention includes a phonetic alphabet with clarifiers and modifiers that aid in the teaching of reading skills to individuals with dyslexia, dyscalculia, and other neurological impairments when the present invention letters are connected horizontally in series with clarifiers and modifiers to form a word, a phrase, a sentence, and / or a paragraph. The present invention further includes mathematical symbols for teaching math skills to individuals with dyslexia, dyscalculia, and other neurological impairments when predetermined geometric shapes are arranged to form numbers of a base 10 counting system that are capable for using in additional, subtraction, multiplication, division. The present invention of mathematical symbols includes whole numbers, real numbers, integers, fractions, and decimals. The present invention also includes 2D and 3D tools and methods of using same.
Owner:CORNELL MICHAEL E

Methods for teaching reading and math skills to individuals with dyslexia, dyscalculia, and other neurological impairments

The present invention includes mathematical symbols for teaching math skills to individuals with dyslexia, dyscalculia, and other neurological impairments when unique geometric shapes are arranged to form numbers of a base 10 counting system that are capable for using in additional, subtraction, multiplication, and division. The present invention of mathematical symbols includes whole numbers, real numbers, integers, fractions, and decimals. The present invention also includes a computer implemented digital interactive learning system comprised of having a user manipulating the unique geometrical shapes on a device using an interface. Preferably the interface is comprised of a shape bar area where the various geometrical shapes are displayed and a workspace area where the various geometrical shapes are manipulated by the user. The present invention can be used to teach students how to perform basic math operations and how to use currency.
Owner:CORNELL MICHAEL E

Application of extracellular vesicles derived from mesenchymal stem cells in treatment of subarachnoid hemorrhage

ActiveCN110755450APromote phenotypic transformationImproved prognosisNervous disorderAntipyreticNeurological impairmentCell
The invention provides an application of extracellular vesicles derived from mesenchymal stem cells in treatment of subarachnoid hemorrhage, which belongs to the technical field of molecular biology.The MSCs extracellular vesicles (MSCs-EVs) have the effects of relieving SAH complications, and improving prognosis and the like. Specifically, the MSCs-EVs can effectively improve the neuroinflammation reaction after subarachnoid hemorrhage (SAH), promote the phenotypic transformation of microglial cells to M2, and relieve the symptoms of neurological impairment, cerebral water content increase and the like caused by subarachnoid hemorrhage.
Owner:SHANDONG UNIV QILU HOSPITAL

High potency dopaminergic treatment of neurological impairment associated with brain injury

Methods and compositions are described for treating impaired neurological function, including altered state of consciousness disorders, in an individual who has sustained a brain injury comprising administering to the individual apomorphine. Methods and compositions are described for treating impaired neurological function, including altered state of consciousness disorders, in an individual who has sustained a brain injury comprising administering to the individual at least 1000 mg or more of L-dopa (levodopa) per day. The use of potent dopaminergic agents to stimulate emergence from an altered consciousness state, such as a coma, is disclosed.
Owner:NEUROHEALING PHARMA INC

System for traumatic brain injury detection using oculomotor tests

Embodiments of the present invention comprises apparatuses and methods of measuring levels of neurological impairment. Certain embodiments of the invention comprise a headset that emits light into the user's eyes and the system tracks the pupils' orientation, movement, contraction and dilation. In specific embodiments, the headset can run a battery of tests and calculate a score indicating the user's level of neurological impairment.
Owner:UNIV OF IOWA RES FOUND +1

Chinese medicinal preparation for treating acute ischemic stroke

The invention relates to a Chinese medicinal preparation for treating acute ischemic stroke with a good treatment effect and high safety. The Chinese medicinal preparation is prepared from the following raw materials in parts by weight: 15 parts of red paeony roots, 9 parts of szechuan lovage rhizome, 15 parts of earthworms, 20 parts of danshen roots, 30 parts of siegesbeckia herb, 30 parts of roots of kudzuvine roots, 15 parts of tree peony root bark, 15 parts of twotooth achyranthes roots, 30 parts of suberect spatholobus stems, 15 parts of ground beetles, 9 parts of peach seeds, 6 parts of leeches and 3 parts of safflowers. The Chinese medicinal preparation provided by the invention is effective in treatment of both symptoms and root causes and has the efficacies of combining warming and heat clearing, promoting the circulation of qi and blood, dispersing blood stasis, dredging collaterals, relaxing muscles and relieving muscular spasm. The Chinese medicinal preparation has a significant effect of improving the neurological impairment of a patient with the acute ischemic stroke due to qi deficiency and blood stasis without causing adverse effects on liver and kidney functions, urine and blood routine, and in addition, the Chinese medicinal preparation can be used for treating acute ischemic stroke safely.
Owner:胡万华

3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission

The present invention relates to novel 3-phenyl-3-methoxy-pyrrolidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-3-methoxy-pyrrolidine derivatives of the invention and to the use of these compounds for therapeutic applications.
Owner:INTEGRATIVE RES LAB SWEDEN

Polyphenol derivative compound 6-CEPN as therapeutic agent for acute ischemic stroke

A novel flavonoid derivative compound 6-CEPN can protect a brain against ischemia / reperfusion (I / R) injury by attenuating peroxynitrite-mediated mitochondrial autophagy. The infarct volume and neurological impairment score of acute ischemic stroke is significantly improved by 6-CEPN. It is found that the 6-CEPN inhibites excess mitochondrial autophagy activation during brain I / R injury, accompanied by a reduction in the production of peroxynitrite. Specifically, the 6-CEPN inhibites the expression ratio of LC3-II / I and Drp1 in the mitochondrial fraction in a dose-dependent manner, as well as the protein expression of the iNOS and NADPPH oxidase subunit p47phox.
Owner:THE UNIVERSITY OF HONG KONG

Lipid emulsions in the treatment of systemic poisoning

The present invention provides lipid emulsions and methods of intravenously administering lipid emulsions to treat systemic toxicity caused by foreign lipophilic and amphiphilic substances. In particular, methods are provided to treat cardiovascular impairment, such as cardiotoxicity, asystole and ischemia of the brain and heart, and neurological impairments, such as seizures and comas, caused by foreign lipophilic and amphiphilic substances, including cardiovascular impairment caused by local anesthetics, tricyclic antidepressants, sodium channel blockers, and calcium channel blockers.
Owner:RESQ PHARMA INC

Application of CPAG-1 in preparation of ischemic brain injury neuroprotective agent medicine

The invention discloses an application of CPAG-1 in preparation of a neuroprotective agent drug for ischemic brain injury. Belongs to the technical field of brain injury medicines. The CPAG-1 disclosed by the invention is used for preparing a neuroprotective agent medicine for ischemic brain injury to play a brain protection role in ischemic brain injury, specifically, the CPAG-1 can be used for reducing the volume of cerebral infarction and relieving encephaledema after infarction, and meanwhile, the CPAG-1 can be used for remarkably reducing neurological impairment of MCAO mice and promoting the recovery of feeling and movement after stroke.
Owner:XUZHOU MEDICAL UNIV

Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists

The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.
Owner:JANSSEN PHARMA NV

Application of MST4 related substances in preparation of medicine for treating neuroinflammation reaction after cerebral hemorrhage

The invention discloses an application of an MST4 related substance as the following (a) and / or (b) and / or (c) and / or (d) and / or (e) and / or (f) and / or (g): (a) preparing a substance for promoting expression of MST4 and NLRP3; (b) preparing a substance for inhibiting MST4 expression; (c) preparing a substance for inhibiting the expression of NLRP3; (d) preparing a substance for inhibiting the expression of MST4 and promoting the expression of NLRP3; (e) preparing a substance for inhibiting release of IL-1beta and TNF-alpha; (f) preparing substances for preventing and / or treating neurological impairment and encephaledema; and (g) preparing a substance for preventing and / or treating neuroinflammation reaction after cerebral hemorrhage. The test proves that the MCC950 inhibits the interaction of the MST4 and the NLRP3 to inhibit the neuroinflammatory reaction after cerebral hemorrhage; compared with a sham group, the expression of endogenous MST4 and NLRP3 after ICH is increased, and MST4 and NLRP3 are co-localized in microglial cells respectively; the MCC950 obviously alleviates neurological impairment and encephaledema, and has no influence on the expression of MST4 protein.
Owner:THE FIRST AFFILIATED HOSPITAL OF WANNAN MEDICAL COLLEGE YIJISHAN HOSPITAL OF WANNAN MEDICAL COLLEGE

New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

The present invention provides compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-(disubstituted aryl)-pyrrolidines for the treatment of central nervous system disorders.
Owner:NSAB FILIAL AF NEUROSEARCH SVERIGE

Novel lower limb functional training rehabilitation equipment for neurology department

The invention relates to rehabilitation equipment for a neurology department, in particular to novel lower limb functional training rehabilitation equipment for the neurology department. The novel lower limb functional training rehabilitation equipment comprises a rehabilitation chair backrest, movable supporting legs, a pedal plate, a multifunctional device, a rehabilitation chair seat board, fastening bolts, fastening screws, an arm nerve exercising device, a finger nerve exercising device and circular through hole. The device integrates leg training, arm training and finger training and facilitates the training of neurological disorder patients, is simple in structure and is convenient to operate. The rehabilitation chair backrest is in movable contact and connection with the movable supporting legs; the movable supporting legs are in movable contact and connection with the rehabilitation chair seat board; the rehabilitation chair backrest is in fixed contact and connection with therehabilitation chair seat board by the fastening screws; the multifunctional device is in movable contact and connection with the rehabilitation chair seat board; the pedal plate is in movable contact and connection with the multifunctional device by the fastening bolts; the arm nerve exercising device corresponds to the multifunctional device through a groove; the finger nerve exercising devicecorresponds to the multifunctional device by a groove.
Owner:陈文
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products